LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 213

Search options

  1. Book: Special issue: Autoimmunity in primary immunodeficiency

    Carneiro-Sampaio, Magda

    (Journal of clinical immunology ; 28, Suppl. 1)

    2008  

    Title variant Autoimmunity in primary immunodeficiency
    Author's details guest ed.: Magda Carneiro-Sampaio
    Series title Journal of clinical immunology ; 28, Suppl. 1
    Collection
    Language English
    Size S90 S. : Ill.
    Publisher Springer
    Publishing place New York
    Publishing country United States
    Document type Book
    HBZ-ID HT015631453
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

  2. Article ; Online: The double-edged sword: COVID-19 pandemic-related delay in immune maturation in young children.

    Sousa, Braian Lucas Aguiar / Carneiro-Sampaio, Magda Maria Sales

    Clinics (Sao Paulo, Brazil)

    2023  Volume 78, Page(s) 100239

    MeSH term(s) Child ; Humans ; Child, Preschool ; COVID-19 ; Pandemics ; SARS-CoV-2
    Language English
    Publishing date 2023-06-16
    Publishing country United States
    Document type Editorial
    ZDB-ID 2182801-5
    ISSN 1980-5322 ; 1807-5932
    ISSN (online) 1980-5322
    ISSN 1807-5932
    DOI 10.1016/j.clinsp.2023.100239
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Humanization: Improving patient and family experience in a public pediatric hospital.

    Zimmermann, Jussara de Oliveira / Sampaio, Anna-Dulce S C / Kudo, Aide Mitie / Carneiro-Sampaio, Magda

    Clinics (Sao Paulo, Brazil)

    2023  Volume 78, Page(s) 100187

    MeSH term(s) Humans ; Child ; Hospitals, Pediatric ; Hospitals, Public
    Language English
    Publishing date 2023-04-02
    Publishing country United States
    Document type Editorial
    ZDB-ID 2182801-5
    ISSN 1980-5322 ; 1807-5932
    ISSN (online) 1980-5322
    ISSN 1807-5932
    DOI 10.1016/j.clinsp.2023.100187
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Reduced expressions of apoptosis-related proteins TRAIL, Bcl-2, and TNFR1 in NK cells of juvenile-onset systemic lupus erythematosus patients: relations with disease activity, nephritis, and neuropsychiatric involvement.

    Liphaus, Bernadete L / Silva, Simone C / Palmeira, Patrícia / Silva, Clovis A / Goldenstein-Schainberg, Claudia / Carneiro-Sampaio, Magda

    Frontiers in immunology

    2024  Volume 15, Page(s) 1327255

    Abstract: Background: Lupus pathogenesis is mainly ascribed to increased production and/or impaired clearance of dead cell debris. Although self-reactive T and B lymphocytes are critically linked to lupus development, neutrophils, monocytes, and natural killer ( ... ...

    Abstract Background: Lupus pathogenesis is mainly ascribed to increased production and/or impaired clearance of dead cell debris. Although self-reactive T and B lymphocytes are critically linked to lupus development, neutrophils, monocytes, and natural killer (NK) cells have also been implicated. This study assessed apoptosis-related protein expressions in NK cells of patients with juvenile-onset systemic lupus erythematosus (jSLE) and relations to disease activity parameters, nephritis, and neuropsychiatric involvement.
    Methods: Thirty-six patients with jSLE, 13 juvenile dermatomyositis (JDM) inflammatory controls, and nine healthy controls had Fas, FasL, TRAIL, TNFR1, Bcl-2, Bax, Bim, and caspase-3 expressions in NK cells (CD3-CD16+CD56+) simultaneously determined by flow cytometry. Disease activity parameters included Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score, erythrocyte sedimentation rate, C-reactive protein level, anti-double strain DNA antibody level, complement fractions C3 and C4 levels.
    Results: Patients with jSLE had a profile of significantly reduced expression of TRAIL, Bcl-2, and TNFR1 proteins in NK cells when compared to healthy controls. Similar profile was observed in patients with jSLE with active disease, positive anti-dsDNA, nephritis, and without neuropsychiatric involvement. Patients with jSLE with positive anti-dsDNA also had reduced expression of Bax in NK cells when compared healthy controls and to those with negative anti-dsDNA. Yet, patients with jSLE with negative anti-dsDNA had reduced mean fluorescence intensity (MFI) of Bim in NK cells compared to healthy controls. Patients with jSLE with nephritis also had reduced MFI of Fas in NK cells when compared to those without nephritis. In addition, in patients with jSLE, the proportion of FasL-expressing NK cells directly correlated with the SLEDAI-2K score (rs = 0.6, p = 0.002) and inversely correlated with the C3 levels (rs = -0.5, p = 0.007). Moreover, patients with jSLE had increased NK cell percentage and caspase-3 protein expression in NK cells when compared to JDM controls.
    Conclusion: This study extends to NK cells an altered profile of TRAIL, Bcl-2, TNFR1, Fas, FasL, Bax, Bim, and caspase-3 proteins in patients with jSLE, particularly in those with active disease, positive anti-dsDNA, nephritis, and without neuropsychiatric involvement. This change in apoptosis-related protein expressions may contribute to the defective functions of NK cells and, consequently, to lupus development. The full clarification of the role of NK cells in jSLE pathogenesis may pave the way for new therapies like those of NK cell-based.
    MeSH term(s) Humans ; Antibodies, Antinuclear ; Apoptosis ; bcl-2-Associated X Protein ; Caspase 3 ; Dermatomyositis/complications ; Killer Cells, Natural ; Lupus Erythematosus, Systemic ; Lupus Nephritis ; Receptors, Tumor Necrosis Factor, Type I
    Chemical Substances Antibodies, Antinuclear ; bcl-2-Associated X Protein ; Caspase 3 (EC 3.4.22.-) ; Receptors, Tumor Necrosis Factor, Type I ; TNFRSF1A protein, human ; TNFSF10 protein, human ; BCL2 protein, human
    Language English
    Publishing date 2024-03-18
    Publishing country Switzerland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2606827-8
    ISSN 1664-3224 ; 1664-3224
    ISSN (online) 1664-3224
    ISSN 1664-3224
    DOI 10.3389/fimmu.2024.1327255
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Maternal vaccination as an additional approach to improve the protection of the nursling: Anti-infective properties of breast milk.

    Zheng, Yingying / Correa-Silva, Simone / Palmeira, Patricia / Carneiro-Sampaio, Magda

    Clinics (Sao Paulo, Brazil)

    2022  Volume 77, Page(s) 100093

    Abstract: Human milk constitutes a secretion with unique functions of both nourishing the nursling and providing protection against enteric and respiratory infections, mainly due to its content of secretory IgA antibodies but also due to the presence of a plethora ...

    Abstract Human milk constitutes a secretion with unique functions of both nourishing the nursling and providing protection against enteric and respiratory infections, mainly due to its content of secretory IgA antibodies but also due to the presence of a plethora of bioactive factors. Specific IgA antibodies are produced locally by plasma cells derived from B lymphocytes that migrate from other mucosae to the mammary gland during lactation, particularly from the gastrointestinal and respiratory tracts. Therefore, here, the authors will provide a comprehensive review of the content and functions of different nutritional and bioactive anti-infectious components from breast milk, such as oligosaccharides, lactoferrin, haptocorrin, α-lactalbumin, k-casein, lysozyme, lactoperoxidase, mucin, fatty acids, defensins, cytokines and chemokines, hormones and growth factors, complement proteins, leukocytes and nucleic acids, including microRNAs, among many others, and the induction of antibody responses in breast milk after maternal vaccination with several licensed vaccines, including the anti-SARS-CoV-2 vaccine preparations used worldwide. Currently, in the midst of the pandemic, maternal vaccination has re-emerged as a crucial source of passive immunity to the neonate through the placenta and breastfeeding, considering that maternal vaccination can induce specific antibodies if performed during pregnancy and after delivery. There have been some reports in the literature about milk IgA antibodies induced by bacterial antigens or inactivated virus vaccines, such as anti-diphtheria-tetanus-pertussis, anti-influenza viruses, anti-pneumococcal and meningococcal polysaccharide preparations. Regarding anti-SARS-CoV-2 vaccines, most studies demonstrate elevated levels of specific IgA and IgG antibodies in milk with virus-neutralizing ability after maternal vaccination, which represents an additional approach to improve the protection of the nursling during the entire breastfeeding period.
    MeSH term(s) Breast Feeding ; COVID-19 ; Female ; Humans ; Immunoglobulin A ; Infant, Newborn ; Milk, Human ; Pregnancy ; Vaccination
    Chemical Substances Immunoglobulin A
    Language English
    Publishing date 2022-08-10
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2182801-5
    ISSN 1980-5322 ; 1807-5932
    ISSN (online) 1980-5322
    ISSN 1807-5932
    DOI 10.1016/j.clinsp.2022.100093
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Inborn Errors of Immunity With Fetal or Perinatal Clinical Manifestations.

    Carneiro-Sampaio, Magda / de Jesus, Adriana Almeida / Bando, Silvia Yumi / Moreira-Filho, Carlos Alberto

    Frontiers in pediatrics

    2022  Volume 10, Page(s) 891343

    Abstract: In this article we revised the literature on Inborn Errors of Immunity (IEI) keeping our focus on those diseases presenting with intrauterine or perinatal clinical manifestations. We opted to describe our findings according to the IEI categories ... ...

    Abstract In this article we revised the literature on Inborn Errors of Immunity (IEI) keeping our focus on those diseases presenting with intrauterine or perinatal clinical manifestations. We opted to describe our findings according to the IEI categories established by the International Union of Immunological Societies, predominantly addressing the immunological features of each condition or group of diseases. The main finding is that such precocious manifestations are largely concentrated in the group of primary immune regulatory disorders (PIRDs) and not in the group of classical immunodeficiencies. The IEI categories with higher number of immunological manifestations
    Language English
    Publishing date 2022-05-06
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2711999-3
    ISSN 2296-2360
    ISSN 2296-2360
    DOI 10.3389/fped.2022.891343
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus.

    Trindade, Vitor Cavalcanti / Carneiro-Sampaio, Magda / Bonfa, Eloisa / Silva, Clovis Artur

    Paediatric drugs

    2021  Volume 23, Issue 4, Page(s) 331–347

    Abstract: Childhood-onset systemic lupus erythematosus (cSLE) is a prototype of a multisystemic, inflammatory, heterogeneous autoimmune condition. This disease is characterized by simultaneous or sequential organ and system involvement, with unpredictable flare ... ...

    Abstract Childhood-onset systemic lupus erythematosus (cSLE) is a prototype of a multisystemic, inflammatory, heterogeneous autoimmune condition. This disease is characterized by simultaneous or sequential organ and system involvement, with unpredictable flare and high levels of morbidity and mortality. Racial/ethnic background, socioeconomic status, cost of medications, difficulty accessing health care, and poor adherence seem to impact lupus outcomes and treatment response. In this article, the management of cSLE patients is updated. Regarding pathogenesis, a number of potential targets for drugs have been studied. However, most treatments in pediatric patients are off-label drugs with recommendations based on inadequately powered studies, therapeutic consensus guidelines, or case series. Management practices for cSLE patients include evaluations of disease activity and cumulative damage scores, routine non-live vaccinations, physical activity, and addressing mental health issues. Antimalarials and glucocorticoids are still the most common drugs used to treat cSLE, and hydroxychloroquine is recommended for nearly all cSLE patients. Disease-modifying antirheumatic drugs (DMARDs) should be standardized for each patient, based on disease flare and cSLE severity. Mycophenolate mofetil or intravenous cyclophosphamide is suggested as induction therapy for lupus nephritis classes III and IV. Calcineurin inhibitors (cyclosporine, tacrolimus, voclosporin) appear to be another good option for cSLE patients with lupus nephritis. Regarding B-cell-targeting biologic agents, rituximab may be used for refractory lupus nephritis patients in combination with another DMARD, and belimumab was recently approved by the US Food and Drug Administration for cSLE treatment in children aged > 5 years. New therapies targeting CD20, such as atacicept and telitacicept, seem to be promising drugs for SLE patients. Anti-interferon therapies (sifalimumab and anifrolumab) have shown beneficial results in phase II randomized control trials in adult SLE patients, as have some Janus kinase inhibitors, and these could be alternative treatments for pediatric patients with severe interferon-mediated inflammatory disease in the future. In addition, strict control of proteinuria and blood pressure is required in cSLE, especially with angiotensin-converting enzyme inhibitor and angiotensin receptor blocker use.
    MeSH term(s) Age of Onset ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antirheumatic Agents/therapeutic use ; Child ; Disease Management ; Glucocorticoids/therapeutic use ; Humans ; Immunosuppressive Agents/therapeutic use ; Immunotherapy/methods ; Lupus Erythematosus, Systemic/diagnosis ; Lupus Erythematosus, Systemic/drug therapy ; Lupus Erythematosus, Systemic/immunology ; Mycophenolic Acid/therapeutic use ; Randomized Controlled Trials as Topic
    Chemical Substances Antibodies, Monoclonal, Humanized ; Antirheumatic Agents ; Glucocorticoids ; Immunosuppressive Agents ; anifrolumab (38RL9AE51Q) ; Mycophenolic Acid (HU9DX48N0T)
    Language English
    Publishing date 2021-07-10
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 1492748-2
    ISSN 1179-2019 ; 1174-5878
    ISSN (online) 1179-2019
    ISSN 1174-5878
    DOI 10.1007/s40272-021-00457-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Successful Treatment of Sinusitis with Topical Human Milk in a Lymphoma Patient Using Rituximab.

    Yamaguchi, Nise / Palmeira, Patricia / Carneiro-Sampaio, Magda

    Journal of clinical immunology

    2019  Volume 39, Issue 3, Page(s) 231–233

    MeSH term(s) Administration, Intranasal ; Administration, Topical ; Aged ; Animals ; Antineoplastic Agents/therapeutic use ; Female ; Humans ; Immunoglobulin A/metabolism ; Lymphoma, Non-Hodgkin/therapy ; Milk ; Milk Proteins/therapeutic use ; Rituximab/therapeutic use ; Serum ; Sinusitis/therapy ; Treatment Outcome
    Chemical Substances Antineoplastic Agents ; Immunoglobulin A ; Milk Proteins ; Rituximab (4F4X42SYQ6)
    Language English
    Publishing date 2019-04-06
    Publishing country Netherlands
    Document type Case Reports ; Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 779361-3
    ISSN 1573-2592 ; 0271-9142
    ISSN (online) 1573-2592
    ISSN 0271-9142
    DOI 10.1007/s10875-019-00620-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Patient with agammaglobulinemia produces anti-SARS-CoV-2 reactive T-cells after CoronaVac vaccine.

    Oshiro, Telma Miyuki / da Silva, Lais Teodoro / Ortega, Marina Mazzilli / Perazzio, Sandro Felix / Duarte, Alberto Jose da Silva / Carneiro-Sampaio, Magda

    Clinics (Sao Paulo, Brazil)

    2022  Volume 77, Page(s) 100007

    MeSH term(s) Agammaglobulinemia ; COVID-19 ; Humans ; SARS-CoV-2 ; T-Lymphocytes ; Vaccines
    Chemical Substances Vaccines
    Language English
    Publishing date 2022-02-02
    Publishing country United States
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 2182801-5
    ISSN 1980-5322 ; 1807-5932
    ISSN (online) 1980-5322
    ISSN 1807-5932
    DOI 10.1016/j.clinsp.2022.100007
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Immunology of breast milk.

    Palmeira, Patricia / Carneiro-Sampaio, Magda

    Revista da Associacao Medica Brasileira (1992)

    2016  Volume 62, Issue 6, Page(s) 584–593

    Abstract: In the critical phase of immunological immaturity of the newborn, particularly for the immune system of mucous membranes, infants receive large amounts of bioactive components through colostrum and breast milk. Colostrum is the most potent natural immune ...

    Abstract In the critical phase of immunological immaturity of the newborn, particularly for the immune system of mucous membranes, infants receive large amounts of bioactive components through colostrum and breast milk. Colostrum is the most potent natural immune booster known to science. Breastfeeding protects infants against infections mainly via secretory IgA (SIgA) antibodies, but also via other various bioactive factors. It is striking that the defense factors of human milk function without causing inflammation; some components are even anti-inflammatory. Protection against infections has been well evidenced during lactation against, e.g., acute and prolonged diarrhea, respiratory tract infections, including otitis media, urinary tract infection, neonatal septicemia, and necrotizing enterocolitis. The milk's immunity content changes over time. In the early stages of lactation, IgA, anti-inflammatory factors and, more likely, immunologically active cells provide additional support for the immature immune system of the neonate. After this period, breast milk continues to adapt extraordinarily to the infant's ontogeny and needs regarding immune protection and nutrition. The need to encourage breastfeeding is therefore justifiable, at least during the first 6 months of life, when the infant's secretory IgA production is insignificant.
    MeSH term(s) Colostrum/chemistry ; Colostrum/immunology ; Humans ; Immune System/immunology ; Milk, Human/chemistry ; Milk, Human/immunology
    Language English
    Publishing date 2016-09
    Publishing country Brazil
    Document type Journal Article ; Review
    ZDB-ID 2027973-5
    ISSN 1806-9282 ; 0104-4230
    ISSN (online) 1806-9282
    ISSN 0104-4230
    DOI 10.1590/1806-9282.62.06.584
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top